via University of Oxford
A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms.
A University of Oxford study published in Clinical Cancer Research, a journal of the American Association for Cancer Research, outlines a new type of blood test that can be used to detect a range of cancers and whether these cancers have spread (metastasised) in the body.
The study analysed samples from 300 patients with non-specific but concerning symptoms of cancer, such as fatigue and weight loss, who were recruited through the Oxfordshire Suspected CANcer (SCAN) pathway.
The researchers assessed whether the test could distinguish patients with a range of solid tumours from those without cancer. Their results show that cancer was correctly detected in 19 out of every 20 patients with cancer using this test. In those with cancer, metastatic disease was identified with an overall accuracy of 94%. These results make this the first technology to be able to determine the metastatic status of a cancer from a simple blood test, without prior knowledge of the primary cancer type.
This test shows promise to help clinicians detect cancer and assess cancer stage in the future. Unlike many blood-based tests for cancer, which detect genetic material from tumours, this test uses a technique called NMR metabolomics, which uses high magnetic fields and radio waves to profile levels of natural chemicals (metabolites) in the blood.
Healthy individuals, people with localised cancer, and people with metastatic cancer each have different profiles of blood metabolites, which can be detected and then analysed by the researchers’ algorithms to distinguish between these states.
Dr James Larkin, researcher on the study from the University of Oxford, says: ‘Cancer cells have unique metabolomic fingerprints due to their different metabolic processes. We are only now starting to understand how metabolites produced by tumours can be used as biomarkers to accurately detect cancer. We have already demonstrated that this technology can successfully identify if patients with multiple sclerosis are progressing to the later stages of disease, even before trained clinicians could tell. It is very exciting that the same technology is now showing promise in other diseases, like cancer.’
Cancers detected earlier are more likely to be treated successfully. This rapid and inexpensive test could help to overcome many barriers to the early detection of cancer, especially in patients that present with non-specific symptoms, which do not direct investigations towards a specific organ. NHS Rapid Diagnostic Centres, similar to Oxfordshire’s SCAN pathway, are currently being set up across the NHS to support faster and earlier cancer diagnosis in all patients with symptoms that could indicate cancer.
This new test is not specific to a single cancer type and has shown promise in this traditionally challenging clinical context, including the potential to detect some cancers in the community before conventional imaging is performed.
Dr Fay Probert, lead researcher of the study from the University of Oxford, says: ‘This work describes a new way of identifying cancer. The goal is to produce a test for cancer that any GP can request. We envisage that metabolomic analysis of the blood will allow accurate, timely and cost-effective triaging of patients with suspected cancer, and could allow better prioritisation of patients based on the additional early information this test provides on their disease.’
Future studies with larger patient cohorts will further evaluate this technique for the earlier detection of new cancers and potential clinical applications.
Original Article: New test can identify if a patient has cancer and if it has spread
More from: University of Oxford
The Latest on: Cancer blood test
- Demand for Blood Cancer Diagnostics CBC Tests in Independent Diagnostic Laboratories has seen a Major Boost – Fact.MR Analysison January 24, 2022 at 6:28 pm
In a recent study, Fact.MR provides a market projection and analysis for the Blood Cancer Diagnostics CBC Tests market from 2017 to 2022. The global Blood Cancer Diagnostics CBC Tests market is ...
- Blood test could detect recurrent melanoma up to a year before scanson January 23, 2022 at 1:39 am
A 72-year-old man has become the first patient to enrol in a UK trial to detect recurrent melanoma up to a year before it can be picked up by scans.Paul Smith, from Bury in Greater Manchester, has had ...
- Landmark CIRCULATE-Japan Study Shows Natera's Signatera™ MRD Test is Predictive of Chemotherapy Benefit in Colorectal Canceron January 22, 2022 at 11:22 am
The oral presentation included an updated analysis from the landmark CIRCULATE-Japan trial analyzing a cohort of colorectal cancer (CRC) patients. More than 3,000 CRC patients are now enrolled in ...
- Blood Test Identifies Pancreatic Cancer in Patients With New-Onset Diabeteson January 21, 2022 at 2:27 pm
Bluestar Genomics’ cell-free DNA blood test identified pancreatic cancer in patients with newly diagnosed diabetes with sensitivity outcomes in the 50 percent range and specificity in the high 90s.
- Yonsei University: Simple Blood Test for Early Cancer Detection Could Soon Be a Realityon January 20, 2022 at 9:55 pm
Cancer research has come a long way in the past few decades; however, many patients are diagnosed too late, which decreases their odds of survival. Treatment success and patient survival largely ...
- Can a Blood Test Detect Lung Cancer in High-Risk Adults?on January 19, 2022 at 6:30 am
A new study to evaluate the accuracy of a blood test for detecting lung cancer in high-risk adults has enrolled its first participant with plans to enroll thousands more.
- Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adultson January 18, 2022 at 5:05 am
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today the enrollment of the first patient in the SHIELD (Screening for HIgh-frEquency maLignant Disease) LUNG study, ...
- Pancreatic Cancer Test Gets Validated for Newly Diagnosed Diabeteson January 13, 2022 at 3:28 pm
Researchers derived and validated a proprietary screening test to detect pancreatic cancer in people with new-onset diabetes. The test uses an epigenetic analysis of a 20 mL blood specimen.
- Oxford cancer blood test detects tumors and metastasis earlyon January 11, 2022 at 4:50 pm
Cancer treatments have better outcomes if the disease is caught early, but unfortunately symptoms often don’t present until later. A new Oxford study demonstrates an experimental blood test that shows ...
- JPM 2022: Freenome passes $1B funding mark with $290M from Roche for cancer blood testson January 11, 2022 at 4:00 am
The latest of the blood testing company’s supersized fundraises came barely a month after its $300 million predecessor.
via Bing News
The Latest on: Cancer blood test
via Google News